ArticleNeurochemical research2020
Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.
Article in Neurochemical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Phytomedicines in preclinical and clinical research on antipsychotics-induced EPS/EPS-like behaviors: therapeutic effects and neurobiological mechanisms.Frontiers in psychiatry · 2026Review
- Heterocyclic Derivatives in Parkinson's Therapy: Recent Advances and Prospects.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Rosa moschata leaf extract modulates complete freund's adjuvant-induced polyarthritis in Wistar rats via regulation of pro-inflammatory and inflammatory biomarkers.Inflammopharmacology · 2025Article
- Spirilloxanthin from Verbesina encelioides Flower Extract has Neuroprotective Benefits in Scopolamine-Induced Memory Impaired Rats that Resemble Alzheimer's Disease.Molecular neurobiology · 2025Article
- Acute, sub-acute and developmental toxicity studies of molybdenum disulfide nanoflowers in rats, as per OECD guidelines.BMC pharmacology & toxicology · 2025Article
- Ipomoea carnea Jacq. ameliorates formalin-induced paw inflammation in rats through modulation of oxidative and inflammatory pathways.Inflammopharmacology · 2025Article
- Neuroprotective effects of bavachalcone in a mouse model of Parkinson's disease: linking the gut-brain axis and systemic metabolism.Frontiers in neuroscience · 2025Article
- Sofalcone attenuates neurodegeneration in MPTP-induced mouse model of Parkinson's disease by inhibiting oxidative stress and neuroinflammation.Molecular biology reports · 2024Article
- Biochemical properties and biological potential of Syzygium heyneanum with antiparkinson's activity in paraquat induced rodent model.PloS one · 2024Article
- The curative and mechanistic acumen of curcuminoids formulations against haloperidol induced Parkinson's disease animal model.Metabolic brain disease · 2023Article
- Neuroprotective potential ofFrontiers in pharmacology · 2023Article
- Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Chalcones as Potential Ligands for the Treatment of Parkinson's Disease.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson's diseases.Environmental science and pollution research international · 2022Article
- Pharmacological Potential of the Standardized Methanolic Extract ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- The Role of Mitochondrial Genes in Neurodegenerative Disorders.Current neuropharmacology · 2022Review
- Antiparkinsonian activity of Cucurbita pepo seeds along with possible underlying mechanism.Metabolic brain disease · 2021Article
- Toxicological Screening of 4-Phenyl-3,4-dihydrobenzo[ACS omega · 2021Article
- Screening of Synthetic Isoxazolone Derivative Role in Alzheimer's Disease: Computational and Pharmacological Approach.Neurochemical research · 2021Article
- Acute Oral, Subacute, and Developmental Toxicity Profiling of Naphthalene 2-Yl, 2-Chloro, 5-Nitrobenzoate: Assessment Based on Stress Response, Toxicity, and Adverse Outcome Pathways.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder of dopaminergic, noradrenergic, and serotonergic systems, in which dopamine, noradrenaline, and serotonin levels are depleted and lead to the development of motor and non-motor symptoms such as tremor, bradykinesia, weight changes, fatigue, depression, and visual hallucinations. Therapeutic strategies place much focus on dopamine replacement and the inhibition of dopamine metabolism. The present study was based on the known abilities of chalcones to act as molecular scaffolds that selectively inhibit MAO-B with the added advantage of binding reversibly. Recently, we synthesized a series of 26 chalcone compounds, amongst which (2E)-1-(2H-1,3-benzodioxol-5-yl)-3-(4-fluorophenyl)prop-2-en-1-one (O10) and (2E)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(4-fluorophenyl)prop-2-en-1-one (O23) most inhibited MAO-B. Hence, the present study was performed to explore the molecular mechanisms responsible for the neuroprotective effect of O10 and O23 at varying doses such as 10, 20, and 30 mg/kg each in a haloperidol-induced murine model of PD. Both compounds were effective (though O23 was the more effective) at ameliorating extrapyramidal and non-motor symptoms in the model and improved locomotory and exploratory behaviors, reduced oxidative stress markers, and enhanced antioxidant marker and neurotransmitter levels. Furthermore, histopathological studies showed O10 and O23 both reduced neurofibrillary tangles and plaques to almost normal control levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.